Nektar Therapeutics Contract with Customer, Asset, Reclassified to Receivable
Nektar Therapeutics (NKTR) reported Contract with Customer, Asset, Reclassified to Receivable of $200.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-26.
Discontinued › Notes › Change in Contract with Customer, Asset and Liability
us-gaap:ContractWithCustomerAssetReclassifiedToReceivable · last filed 2021-02-26
- Nektar Therapeutics contract with customer, asset, reclassified to receivable for fiscal 2020 was $200.00K, a 98.44% decline from fiscal 2019.
- Nektar Therapeutics contract with customer, asset, reclassified to receivable for fiscal 2019 was $12.80M, a 47.11% decline from fiscal 2018.
- Nektar Therapeutics contract with customer, asset, reclassified to receivable for fiscal 2018 was $24.20M, a 633.33% increase from fiscal 2017.
- Nektar Therapeutics contract with customer, asset, reclassified to receivable for fiscal 2017 was $3.30M.
| Period end | Contract with Customer, Asset, Reclassified to Receivable 12 month |
|---|---|
| 2020-12-31 | $200.00K 10-K · filed 2021-02-26 |
| 2019-12-31 | $12.80M 10-K · filed 2021-02-26 |
| 2018-12-31 | $24.20M 10-K · filed 2020-02-28 |
| 2017-12-31 | $3.30M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |